|
⚲
|
| Keyboard |
| Lilly Ventures Fund I LLC
✚
|
|
|---|---|
| CIK # | 0001575852 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001575852] | |
| 4 | [0001575852] | |
| SC 13D | [0001575852] | |
| SC 13G | [0001575852] |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Surface Oncology Inc SURF
Series A Preferred Stock · derivative
|
2018-04-23 | Conversion | 7,000,000 | ||
|
Surface Oncology Inc SURF
Common Stock
|
2018-04-23 | Buy | 266,000 | $15.00 | 3,990,000 |
|
Surface Oncology Inc SURF
Common Stock
|
2018-04-23 | Conversion | 3,181,817 | ||
|
Rein Therapeutics Inc ALRN
Series E-2 Preferred Stock · derivative
|
2017-07-05 | Conversion | 1,907,373 | $0.00 | |
|
Rein Therapeutics Inc ALRN
Series F Preferred Stock · derivative
|
2017-07-05 | Conversion | 1,443,972 | $0.00 | |
|
Rein Therapeutics Inc ALRN
Series E-3 Preferred Stock · derivative
|
2017-07-05 | Conversion | 1,654,411 | $0.00 | |
|
Rein Therapeutics Inc ALRN
Common Stock
|
2017-07-05 | Conversion | 844,987 | ||
|
Rein Therapeutics Inc ALRN
Common Stock
|
2017-07-05 | Buy | 250,000 | $15.00 | 3,750,000 |
|
Rein Therapeutics Inc ALRN
Series D Preferred Stock · derivative
|
2017-07-05 | Conversion | 3,390,885 | $0.00 | |
|
Protagonist Therapeutics Inc PTGX
Series B Preferred Stock · derivative
|
2016-08-16 | Conversion | 9,142,857 | $0.00 | |
|
Protagonist Therapeutics Inc PTGX
Series A Preferred Stock · derivative
|
2016-08-16 | Conversion | 3,000,000 | $0.00 | |
|
Protagonist Therapeutics Inc PTGX
Common Stock
|
2016-08-16 | Conversion | 678,712 | ||
|
Protagonist Therapeutics Inc PTGX
Common Stock
|
2016-08-16 | Buy | 583,333 | $12.00 | 6,999,996 |
|
Protagonist Therapeutics Inc PTGX
Common Stock
|
2016-08-16 | Conversion | 206,896 | ||
|
Protagonist Therapeutics Inc PTGX
Common Stock
|
2016-08-16 | Conversion | 630,541 | ||
|
Protagonist Therapeutics Inc PTGX
Series C Preferred Stock · derivative
|
2016-08-16 | Conversion | 9,841,333 | $0.00 | |
|
Coherus Oncology Inc CHRS
Common Stock, $0.0001 par value
|
2014-11-12 | Conversion | 543,101 | ||
|
Coherus Oncology Inc CHRS
Common Stock, $0.0001 par value
|
2014-11-12 | Buy | 164,963 | $13.50 | 2,227,000 |
|
Coherus Oncology Inc CHRS
Common Stock, $0.0001 par value
|
2014-11-12 | Conversion | 2,333,955 | ||
|
Coherus Oncology Inc CHRS
Series C Preferred Stock · derivative
|
2014-11-12 | Conversion | 543,101 | ||
| showing 20 of 35 most recent transactions | |||||